VCNX — Vaccinex Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $2.20m
- $2.78m
- $0.60m
Brief: Vaccinex Completes Enrollment In Phase 1B/2 Signal-Ad (Alzheimer’S Disease) Study Of Pepinemab
Brief: Vaccinex Announces Initiation Of Single-Arm Open Label, Phase Ib/2 Study To Evaluate Pepinemab In Combination With Avelumab As Second Line Combination Immunotherapy For Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft
Brief: Vaccinex Announces First Patient Dosed With Anti-Ccr8 Antibody Licensed To Surface Oncology
Brief: Vaccinex Says Received Notice Of Delisting From Nasdaq
Brief: Vaccinex reports Q2 results
Vaccinex up as Huntington's disease treatment shows promise
Brief: Vaccinex Inc Announces Presentation At The 2022 Alzheimer’s Association International
Brief: Vaccinex Reports First Quarter 2022 Results And Provides Corporate Update
Brief: Vaccinex Files Prospectus Related To Resale From Time To Time By Selling Stockholders Of Up To 3.25 Mln Shares Of Common Stock
U.S. STOCKS ON THE MOVE-Corning, Stride, Gatos Silver
Vaccinex jumps on promising early data for cancer drug
U.S. STOCKS ON THE MOVE-JinkoSolar, Gatos Silver, Vaccinex Inc
Brief: VaccineX Reports Two Complete Responses Study Of Pepinemab In Combination With Keytruda
Brief: Vaccinex Reports Phase Ib Keynote B84 Combination Study Of Keytruda And Pepinemab
Brief: Vaccinex Reports Qtrly Loss Per Share Of $0.17
Vaccinex Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vaccinex Reports Second Quarter 2021 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Tesla, Gap, Fastly, Stitch Fix, Tilray